The same research group performed a preclinical analysis to better characterize the role of the secondary KRAS mutations at the Switch II region in NSCLC patients; double-mutant alleles including Y96C, H95D, and R68S Ba/F3 cells were tested with adagrasib and sotorasib (44).. Here, KRAS is linked to non-small cell lung carcinoma.